Healthcare Capital Partners III, L.P. Venrock, a 10% owner of $ORKA, bought 88,794 shares of the company on 02-14-2025 for an estimated $1,015,803. This trade was ...

MENLO PARK, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a ...

(RTTNews) - Oruka Therapeutics, Inc. (ORKA), Friday announced the preclinical data for ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F. The findings, presented at the ...